Xeris Biopharma Holdings Inc. Stock
Xeris Biopharma Holdings Inc. gained 1.850% today.
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 7 € there is a slightly positive potential of 17.15% for Xeris Biopharma Holdings Inc. compared to the current price of 5.98 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 1.850% | 3.463% | -8.709% | 78.358% | 82.276% | 333.599% | 58.069% |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
Comments
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat